David P. Luci
Known title: President and CEOCIK: 0001271123
David P. Luci's purchase track record
How the stock did after each of David P. Luci's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since November 19, 2021
Stock higher 6 months later
33%
3 months: 0%
Median 6-month return
-45.7%
3 months: -16.8%
Beat the S&P 500
33%
median -28.7% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/6/2025 | ACXP | $50K | -69.9% | -56.8% | +4.3% |
| 7/27/2022 | ACXP | $75K | -16.8% | +7.6% | -0.2% |
| 11/19/2021 | ACXP | $25K | -15.6% | -45.7% | -17.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ACXP | ▲ Buy | Open Market | 49,261 | $50K | 1/6/2025 | View on chart |
| ACXP | ▲ Buy | Option Exercise | 19,737 | $70K | 1/3/2024 | View on chart |
| ACXP | ▲ Buy | Open Market | 19,737 | $75K | 7/27/2022 | View on chart |
| ACXP | ▲ Buy | Open Market | 5,200 | $25K | 11/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Acurx Enrolls First Patient in PATHFINDER C. Diff Trial
Acurx Pharmaceuticals announced that the first patient has been enrolled in its PATHFINDER clinical trial for ibezapolstat, a treatment for multiply-recurrent C. difficile infection. This milestone marks a key step in the drug's development process. The company's stock is currently trading near its 52-week low, while analysts maintain a wide range of price targets.
Acurx Enrolls First Patient in PATHFINDER C. Diff Trial. Acurx Pharmaceuticals announced that the first patient has been enrolled in its PATHFINDER clinical trial for ibezapolstat, a treatment for multiply-recurrent C. difficile infection. This milestone marks a key step in the drug's development process. The company's stock is currently trading near its 52-week low, while analysts maintain a wide range of price targets.